Prenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status.

ABSTRACT:

Background

The association between obesity (body mass index (BMI) ≥ 30 kg/m²) and pattern of medication use during pregnancy in the United States is not well-studied. Higher pre-pregnancy BMI may be associated with increases or decreases in medication use across pregnancy as symptoms (e.g. reflux) or comorbidities (e.g. gestational diabetes) requiring treatment that may be associated with higher BMI could also change with advancing gestation.

Objectives

To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status.

Methods

In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pre

SUBMITTER: Vafai Y 

PROVIDER: S-EPMC8802334 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature